RSV-IGIV

respiratory syncytial virus immune globulin (RSV-IGIV)

an immune serum.
indications It is used in children less than 2 years of age with bronchopulmonary dysplasia or in those born prematurely to prevent serious lower respiratory tract infection caused by respiratory syncytial virus.
contraindications Factors that prohibit its use are hypersensitivity to this drug or to other human immunoglobulin preparations and IgA deficiency.
adverse effects Life-threatening effects are respiratory distress, hypoxia, anaphylaxis, and angioneurotic edema. Other adverse effects are tachypnea, rales, wheezing, fever, hypertension, tachycardia, fluid overload, diarrhea, gastroenteritis, vomiting, rash, overdose effect, and inflammation at the injection site.

RSV-IGIV

Abbreviation for respiratory syncytial virus immune globulin intravenous.
References in periodicals archive ?
Because RSV-IGIV and palivizumab are not effective in the treatment of RSV disease, neither is an approved indication (6).
RSV-IGIV can cause fever, rash, hypotension and, in rare cases, anaphylaxis.
3,4) RSV-IGIV is contraindicated for infants with cyanotic congenital heart disease, but children age 24 months or younger with significant congenital heart disease benefit from palivizumab.
RSV-IGIV (RespiGam, Massachusetts Public Health Biologic Laboratories, and Medimmune, Inc, Gaithersburg, MD) was approved for use by the FDA in 1996 for the prevention of severe RSV infection in those children less than 24 months of age with chronic lung disease or premature birth (35 weeks gestation) (AAP, 1998).
Synagis is also easier to administer than RSV-IGIV (1 intramuscular injection/month vs.
RSV-IGIV or the anti-RSV humanized murine monoclonal antibody can be given during the RSV outbreak season to prevent serious complications of infection in some infants and children at high risk for serious RSV disease (e.